Circulating Cancer Cells / Macrophage HYbrid Cells in Patients With Sarcoma, Part 2

Status: Not yet recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable

Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating cancer cell/macrophage hybrid cells in the peripheral blood and the evolution of this rate over time. The study will be conducted on a population of patients with leiomyosarcoma and treated in the context of routine care. 20 patients will be included: 10 patients with localized disease. 10 patients with metastatic disease. For each included patient, blood samples will be collected during baseline visit and up to 24 months after inclusion.

Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No

• Patient with leiomyosarcoma.

• Diagnosis of sarcoma histologically confirmed by the RRePS network (Réseau de Référence en Pathologie des Sarcomes et des Viscères)

• Localized or metastatic disease

• Newly diagnosed patient who has not yet initiated specific treatment for sarcoma

• Age ≥ 18 years

• Patient affiliated to a Social Security system in France.

• Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedures

Other Locations
Institut Universitaire du Cancer Toulouse - Oncopole
Contact Information
05 31 15 51 70
Time Frame
Start Date: December 2022
Estimated Completion Date: July 2026
Target number of participants: 20
Other: Patient with leiomyosarcoma
Collaborators: Fondation ARC
Leads: Institut Claudius Regaud

This content was sourced from

Similar Clinical Trials